Influence of vitamin D supplementation on plasma lipid profiles: A meta-analysis of randomized controlled trials

Lipids in Health and Disease

Dao-Quan Peng¹  Yang Yang¹  Ning Xia²  Hao Wang¹ 

[1] Department of Cardiology, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, People's Republic of China;Department of Pulmonary, Xiangya Hospital, Central South University, Changsha 410011, Hunan, People's Republic of China

关键词: meta-analysis;    cardiovascular disease;    lipids;    Vitamin D;   

Others  :  1160325
DOI  :  10.1186/1476-511X-11-42

 received in 2012-02-04, accepted in 2012-03-20,  发布年份 2012

【 摘 要 】

Observational studies have shown that low serum levels of vitamin D have been associated with an atherogenic lipid profile. However, the intervention studies gave divergent results. We conducted a meta-analysis of randomized controlled trials that evaluated the effects of vitamin D supplementation on blood lipids. A systematic literature search was conducted via MEDLINE, Cochrane library, and EMBASE for randomized controlled clinical trials assessing the effects of vitamin D supplementation on lipids. The mean change in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) from baseline was treated as a continuous variable. In all, 12 clinical trials consisting of 1346 participants were included in the analysis. The pooled estimate of effect for vitamin D supplementation on LDL-C was 3.23 mg/dl (95% confidence interval, 0.55 to 5.90 mg/dl). No statistically significant effects for vitamin D supplementation were observed for TC, HDL-C and TG (differences in means were 1.52 mg/dl (-1.42 to 4.46 mg/dl), -0.14 mg/dl (-0.99 to 0.71 mg/dl) and -1.92 mg/dl (-7.72 to 3.88 mg/dl) respectively). The lipid modulating effects of vitamin D supplementation should be further investigated though large-scale, randomized trials with adequate doses which can effectively elevated the active form of vitamin D in plasma and with proper population which has hyperlipemia as an inclusion criterion.

【 授权许可】

   
2012 Wang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367(9524):1747-1757.
• [2]Holick MF: Vitamin D deficiency. N Engl J Med 2007, 357(3):266-281.
• [3]Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117(4):503-511.
• [4]Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, Clarke A, Franco OH: Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 2010, 65(3):225-236.
• [5]Wang L, Manson JE, Song Y, Sesso HD: Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010, 152(5):315-323.
• [6]Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, El-Hajj Fuleihan G, Josse RG, Lips P, Morales-Torres J: Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009, 20(11):1807-1820.
• [7]Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF: Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008, 52(24):1949-1956.
• [8]Zittermann A, Schleithoff SS, Koerfer R: Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005, 94(4):483-492.
• [9]Jorde R, Grimnes G: Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res 2011, 50(4):303-312.
• [10]Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17(1):1-12.
• [11]Follmann D, Elliott P, Suh I, Cutler J: Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992, 45(7):769-773.
• [12]Andersen R, Brot C, Mejborn H, Molgaard C, Skovgaard LT, Trolle E, Ovesen L: Vitamin D supplementation does not affect serum lipids and lipoproteins in Pakistani immigrants. Eur J Clin Nutr 2009, 63(9):1150-1153.
• [13]Myrup B, Jensen GF, McNair P: Cardiovascular risk factors during estrogen-norethindrone and cholecalciferol treatment. Arch Intern Med 1992, 152(11):2265-2268.
• [14]Gannage-Yared MH, Azoury M, Mansour I, Baddoura R, Halaby G, Naaman R: Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Investig 2003, 26(8):748-753.
• [15]Major GC, Alarie F, Dore J, Phouttama S, Tremblay A: Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr 2007, 85(1):54-59.
• [16]Schwartz JB: Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009, 85(2):198-203.
• [17]Rajpathak SN, Xue X, Wassertheil-Smoller S, Van Horn L, Robinson JG, Liu S, Allison M, Martin LW, Ho GYF, Rohan TE: Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: Results from the women's health initiative. Am J Clin Nutr 2010, 91(4):894-899.
• [18]Yeksan M, Turk S, Polat M, Cigli A, Erdogan Y: Effects of 1,25 (OH)2D3 treatment on lipid levels in uremic hemodialysis patients. Int J Artif Organs 1992, 15(12):704-707.
• [19]Khajehdehi P: Effect of vitamins on the lipid profile of patients on regular hemodialysis. Scand J Urol Nephrol 2000, 34(1):62-66.
• [20]Khajehdehi P, Taheri S: Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate. J Ren Nutr Offic J Counc Ren Nutr Nat Kidney Found 2003, 13(2):78-83.
• [21]Bonakdaran S, Ayatollahi H, Mojahedi MJ, Sharifipoor F, Shakeri M: Impact of treatment with oral calcitriol on glucose intolerance and dyslipidemia(s) in hemodialysis patients. Saudi J Kidney Dis Transplant Offic Publ Saudi Center Organ Transplant Saudi Arabia 2008, 19(6):942-947.
• [22]Ljunghall S, Lind L, Lithell H, Skarfors E, Selinus I, Sorensen OH, Wide L: Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance-a prospective randomized double-blind study. Acta Med Scand 1987, 222(4):361-367.
• [23]Heikkinen AM, Tuppurainen MT, Niskanen L, Komulainen M, Penttila I, Saarikoski S: Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. Eur J Endocrinol 1997, 137(5):495-502.
• [24]Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C: Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001, 86(4):1633-1637.
• [25]Nagpal J, Pande JN, Bhartia A: A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med J Br Diabet Assoc 2009, 26(1):19-27.
• [26]Zittermann A, Frisch S, Berthold HK, Gotting C, Kuhn J, Kleesiek K, Stehle P, Koertke H, Koerfer R: Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009, 89(5):1321-1327.
• [27]Jorde R, Sneve M, Torjesen P, Figenschau Y: No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 2010, 267(5):462-472.
• [28]Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD: The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2010, 53(10):2112-2119.
• [29]Witham MD, Dove FJ, Sugden JA, Doney AS, Struthers AD: The effect of vitamin D replacement on markers of vascular health in stroke patients - A randomised controlled trial. Nutr Metab Cardiovasc Dis 2010, in press.
• [30]Maki KC, Rubin MR, Wong LG, McManus JF, Jensen CD, Lawless A: Effects of vitamin D supplementation on 25-hydroxyvitamin D, high-density lipoprotein cholesterol, and other cardiovascular disease risk markers in subjects with elevated waist circumference. Int J Food Sci Nutr 2011, 62(4):318-327.
• [31]Sai AJ, Gallagher JC, Fang X: Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: Association with estrogen receptor-(alpha) genotypes. Menopause 2011, 18(10):1101-1112.
• [32]Zittermann A, Gummert JF, Borgermann J: The role of vitamin D in dyslipidemia and cardiovascular disease. Curr Pharm Des 2011, 17(9):933-942.
• [33]Jorde R, Figenschau Y, Hutchinson M, Emaus N, Grimnes G: High serum 25-hydroxyvitamin D concentrations are associated with a favorable serum lipid profile. Eur J Clin Nutr 2011, 64(12):1457-1464.
• [34]Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B: Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006, 84(1):18-28.
• [35]Karhapaa P, Pihlajamaki J, Porsti I, Kastarinen M, Mustonen J, Niemela O, Kuusisto J: Diverse associations of 25-hydroxyvitamin D and 1,25-dihydroxy-vitamin D with dyslipidaemias. J Intern Med 2010, 268(6):604-610.
• [36]Wang JH, Keisala T, Solakivi T, Minasyan A, Kalueff AV, Tuohimaa P: Serum cholesterol and expression of ApoAI, LXRbeta and SREBP2 in vitamin D receptor knock-out mice. J Steroid Biochem Mol Biol 2009, 113(3-5):222-226.
• [37]Wehmeier K, Beers A, Haas MJ, Wong NC, Steinmeyer A, Zugel U, Mooradian AD: Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. Biochim Biophys Acta 2005, 1737(1):16-26.
• [38]Wehmeier KR, Alamir AR, Sultan S, Haas MJ, Wong NC, Mooradian AD: 24, 25-dihydroxycholecalciferol but not 25-hydroxycholecalciferol suppresses apolipoprotein A-I gene expression. Life Sci 2011, 88(1-2):110-116.
• [39]Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113(6):898-918.
• [40]Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF: Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000, 72(3):690-693.